Genomic discovery of potent chromatin insulators for human gene therapy

Nature Biotechnology

Volumn 33, Issue 2, 2015, Pages 198-203

  Liu, Mingdong ^a   Maurano, Matthew T ^b   Wang, Hao ^b   Qi, Heyuan ^a,b   Song, Chao Zhong ^a,b   Navas, Patrick A ^a   Emery, David W ^a,b   Stamatoyannopoulos, John A ^b   Stamatoyannopoulos, George ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; DISEASES; GENES;

GENETIC DISEASE; GENOTOXICITIES; HUMAN GENE THERAPY; HUMAN GENOMES; INSERTIONAL MUTAGENESIS; RECOGNITION SEQUENCE; TUMOR FORMATION; VIRAL VECTORS;

GENE THERAPY;

DEOXYRIBONUCLEASE I; LENTIVIRUS VECTOR; TRANSCRIPTION FACTOR CTCF; VIRUS VECTOR; CCCTC-BINDING FACTOR; CHROMATIN; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER RISK; CARCINOGENESIS; CHROMATIN; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE THERAPY; GENOMICS; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN GENOME; INSULATOR ELEMENT; K562 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; BIOLOGY; ENHANCER REGION; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; METABOLISM;

ANIMALIA;

BINDING SITES; CHROMATIN; COMPUTATIONAL BIOLOGY; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENETIC VECTORS; GENOME, HUMAN; GENOMICS; HUMANS; INSULATOR ELEMENTS; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 84923278709     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3062     Document Type: Article

References (50)

1. Hacein-Bey-Abina, S. et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363, 355-364 (2010).
2. Aiuti, A. et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 447-458 (2009).
3. Cartier, N. et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823 (2009).
4. Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467, 318-322 (2010).
5. Baum, C., Modlich, U., Göhring, G. & Schlegelberger, B. Concise review: managing genotoxicity in the therapeutic modification of stem cells. Stem Cells 29, 1479-1484 (2011).
6. Nienhuis, A.W., Dunbar, C.E. & Sorrentino, B.P. Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 13, 1031-1049 (2006).
7. Emery, D.W. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum. Gene Ther. 22, 761-774 (2011).
8. Gaszner, M. & Felsenfeld, G. Insulators: exploiting transcriptional and epigenetic mechanisms. Nat. Rev. Genet. 7, 703-713 (2006).
9. Chung, J.H., Bell, A.C. & Felsenfeld, G. Characterization of the chicken beta-globin insulator. Proc. Natl. Acad. Sci. USA 94, 575-580 (1997).
10. Chung, J.H., Whiteley, M. & Felsenfeld, G. A 5′ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 74, 505-514 (1993).
11. Bell, A.C., West, A.G. & Felsenfeld, G. The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98, 387-396 (1999).
12. Burgess-Beusse, B. et al. The insulation of genes from external enhancers and silencing chromatin. Proc. Natl. Acad. Sci. USA 99, 16433-16437 (2002).
13. Phillips, J.E. & Corces, V.G. CTCF: master weaver of the genome. Cell 137, 1194-1211 (2009).
14. Giles, K.E., Gowher, H., Ghirlando, R., Jin, C. & Felsenfeld, G. Chromatin boundaries, insulators, and long-range interactions in the nucleus. Cold Spring Harb. Symp. Quant. Biol. 75, 79-85 (2010).
15. Kim, T.H. et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell 128, 1231-1245 (2007).
16. Wang, H. et al. Widespread plasticity in CTCF occupancy linked to DNA methylation. Genome Res. 22, 1680-1688 (2012).
17. Schmidt, D. et al. Waves of retrotransposon expansion remodel genome organization and CTCF binding in multiple mammalian lineages. Cell 148, 335-348 (2012).
18. Parelho, V. et al. Cohesins functionally associate with CTCF on mammalian chromosome arms. Cell 132, 422-433 (2008).
19. Dixon, J.R. et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 485, 376-380 (2012).
20. Emery, D.W., Yannaki, E., Tubb, J. & Stamatoyannopoulos, G. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc. Natl. Acad. Sci. USA 97, 9150-9155 (2000).
21. Arumugam, P.I. et al. Improved human β-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol. Ther. 15, 1863-1871 (2007).
22. Ryu, B.Y., Persons, D.A., Evans-Galea, M.V., Gray, J.T. & Nienhuis, A.W. A chromatin insulator blocks interactions between globin regulatory elements and cellular promoters in erythroid cells. Blood Cells Mol. Dis. 39, 221-228 (2007).
23. Uchida, N., Hanawa, H., Yamamoto, M. & Shimada, T. The chicken hypersensitivity site 4 core insulator blocks promoter interference in lentiviral vectors. Hum. Gene Ther. Methods 24, 117-124 (2013).
24. Li, C.L., Xiong, D., Stamatoyannopoulos, G. & Emery, D.W. Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol. Ther. 17, 716-724 (2009).
25. Ryu, B.Y. et al. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood 111, 1866-1875 (2008).
26. Evans-Galea, M.V. et al. Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vector. Mol. Ther. 15, 801-809 (2007).
27. Renda, M. et al. Critical DNA binding interactions of the insulator protein CTCF: a small number of zinc fingers mediate strong binding, and a single finger-DNA interaction controls binding at imprinted loci. J. Biol. Chem. 282, 33336-33345 (2007).
28. Wendt, K.S. et al. Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature 451, 796-801 (2008).
29. Ohlsson, R., Renkawitz, R. & Lobanenkov, V. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet. 17, 520-527 (2001).
30. Nakahashi, H. et al. A genome-wide map of CTCF multivalency redefines the CTCF code. Cell Rep. 3, 1678-1689 (2013).
31. Li, G. et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell 148, 84-98 (2012).
32. Baum, C. Gene therapy for SCID-X1: focus on clinical data. Mol. Ther. 19, 2103-2104 (2011).
33. Kohn, D.B. & Candotti, F. Gene therapy fulfilling its promise. N. Engl. J. Med. 360, 518-521 (2009).
34. Stein, S. et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198-204 (2010).
35. Dunbar, C.E. & Larochelle, A. Gene therapy activates EVI1, destabilizes chromosomes. Nat. Med. 16, 163-165 (2010).
36. Galy, A. & Thrasher, A.J. Gene therapy for the Wiskott-Aldrich syndrome. Curr. Opin. Allergy Clin. Immunol. 11, 545-550 (2011).
37. Schwarzwaelder, K. et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J. Clin. Invest. 117, 2241-2249 (2007).
38. Deichmann, A. et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 117, 2225-2232 (2007).
39. Aiuti, A. et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J. Clin. Invest. 117, 2233-2240 (2007).
40. Howe, S.J. et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150 (2008).
41. Hacein-Bey-Abina, S. et al. Insertional oncogenesis in 4 patients after retrovirus- mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142 (2008).
42. Seita, J. et al. Gene Expression Commons: an open platform for absolute gene expression profiling. PLoS One 7, e40321 (2012).
43. Song, L. et al. Open chromatin defined by DNasel and FAIRE identifies regulatory elements that shape cell-type identity. Genome Res. 21, 1757-1767 (2011).
44. Xi, H. et al. Identification and characterization of cell type-specific and ubiquitous chromatin regulatory structures in the human genome.PLoS Genet.3, 1377-1388 (2007).
45. Dickson, J. et al. VEZF1 elements mediate protection from DNA methylation. PLoS Genet.6, e1000804 (2010).
46. Kharchenko, P.V., Tolstorukov, M.Y. & Park, P.J. Design and analysis of ChIP-seq experiments for DNA-binding proteins. Nat. Biotechnol. 26, 1351-1359 (2008).
47. Neph, S. et al. BEDOPS: high-performance genomic feature operations. Bioinformatics 28, 1919-1920 (2012).
48. Thurman, R.E. et al. The accessible chromatin landscape of the human genome. Nature 489, 75-82 (2012).
49. Tubb, J., Groth, A.C., Leong, L. & Emery, D.W. Simultaneous sequence transfer into two independent locations of a reporter vector using MultiSite Gateway technology. Biotechniques 39, 553-557 (2005).
50. Aker, M. et al. Core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. Hum. Gene Ther. 18, 333-343 (2007).